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Acute myeloid leukemia (AML) is a heterogeneous disease with poor clinical outcomes. We have 25 
previously shown that constitutive activation of NADPH oxidase 2 (NOX2), resulting in 26 
overproduction of reactive oxygen species (ROS), occurs in over 60% of AML patients. We have 27 
also shown that increased ROS production promotes increased glucose uptake and proliferation in 28 
AML cells, mediated by changes in carbohydrate metabolism. Given that carbohydrate, lipid, and 29 
protein metabolism are all intricately interconnected we aimed to examine the effect of cellular ROS 30 
levels on these pathways and establish further evidence that ROS rewires metabolism in AML. We 31 
carried out metabolomic profiling of AML cell lines in which NOX2-derived ROS production was 32 
inhibited and conversely in cells treated with exogenous H2O2. We report significant ROS-specific 33 
metabolic alterations in sphingolipid metabolism, fatty acid oxidation, purine metabolism, amino acid 34 
homeostasis and glycolysis. These data provide further evidence of ROS directed metabolic changes 35 
in AML and the potential for metabolic targeting as novel therapeutic arm to combat this disease. 36 
  
1 Introduction 37 
Reactive oxygen species (ROS) is the collective term for oxygen containing free radicals and other 38 
reactive molecules, including hydrogen peroxide (H2O2), which exert important cellular functions 39 
both in innate immunity and as cell signaling molecules (Lambeth and Neish, 2014). Physiologically, 40 
production of cellular ROS mainly occurs as a result oxidative phosphorylation in the mitochondria, 41 
or via the transmembrane proteins, nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 42 
family of enzymes (NOX) (Hole et al., 2011). In particular, NOX2, which is expressed on the plasma 43 
membrane of hematopoietic cells, generates  ROS via the univalent reduction of molecular oxygen, 44 
producing extracellular superoxide, which rapidly dismutates to H2O2, either spontaneously or via the 45 
catalytic action of the enzyme superoxide dismutase (Bienert et al., 2006). H2O2 is a relatively long 46 
lived ROS molecule which is able to traverse cell membranes and this, alongside its ability to 47 
reversibly oxidize cysteine residues in the active sites of regulatory proteins, underlies its function as 48 
a cell signaling molecule (Bindoli and Rigobello, 2013). H2O2 plays an integral role in hematopoiesis 49 
both through direct and indirect regulation of gene expression (Prieto-Bermejo et al., 2018;Robinson 50 
et al., 2020). 51 
Previously, using hematopoietic stem progenitor cells as a model for hematopoiesis, we demonstrated 52 
that mutant N-RASG12D promotes ROS production via NADPH oxidase 2 (NOX2) (Hole et al., 53 
2010). We further showed that overproduction of NOX-derived ROS in acute myeloid leukemia 54 
(AML) promotes proliferation which is associated with defective oxidative stress signaling (Hole et 55 
al., 2013). Indeed, over 60% of AML patients show elevated levels of extracellular superoxide and 56 
H2O2 and furthermore these levels correlate with the levels of NOX2 expression (Hole et al., 2013). 57 
To understand the underlying mechanism through which ROS promotes proliferation, we previously 58 
used transcriptome profiling to identify changes in gene expression impacted by ROS over-59 
production (Robinson et al., 2020). We demonstrated that ROS mediated proliferation was attributed 60 
to changes in carbohydrate metabolism, with a key glycolytic regulator, 6-phosphofructo-2-61 
kinase/fructose-2,6-bisphosphatase 3 (PFKFB3), acting as an important mediator of ROS. Elevated 62 
levels of PFKFB3 have been detected in numerous cancers including, colon, prostate, breast, lung, 63 
pancreatic, ovarian, kidney and thyroid (Atsumi et al., 2002).  64 
In addition to carbohydrate metabolism, there are two other main classes of molecules involved in 65 
metabolism, proteins, and lipids. These can be either catabolized to produce energy or synthesized to 66 
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molecules such as nucleotides and structural proteins for the generation of cell membranes. Given 67 
that carbohydrate, lipid, and protein metabolism are all intricately interconnected we aimed to 68 
examine the effect of ROS on these pathways and establish further evidence that ROS rewires 69 
metabolism in AML. Using metabolomic profiling of AML cell lines (in which ROS production was 70 
inhibited by knocking down NOX2 expression) or using a cell line incubated with glucose oxidase 71 
(GOX; an enzyme that produces H2O2), we report significant metabolic alterations in sphingolipid 72 
metabolism, fatty acid oxidation (FAO), purine metabolism, amino acid homeostasis and glycolysis. 73 
2 Materials and Methods 74 
2.1 Materials 75 
Key reagents and resources are provided in below. 76 
Reagent or Resource Source Resource Identifier 
(RRID) or Cat # 
Antibodies 
NOX2-PE MBL Life science Nagoya, Japan, RRID:AB_591389
IgG1-PE Biolegend RRID:AB_326429
 
Chemical, Peptides, Recombinant proteins 
DiogenesTM GeneFlow, Staffordshire U.K. Cat # A2-0092
Diphenyleneiodonium (DPI) Sigma-Aldrich, Poole, U.K Cat # D2926
Glucose Oxidase Sigma-Aldrich, Poole, U.K Cat # G6766
Lipofectamine 3000 Invitrogen, Paisley, U.K Cat # 11668019
7-AAD Sigma-Aldrich, Poole, U.K Cat # SML1633-1ML
NOX2 shRNA Vector Builder  
 
Experimental Models: Cell lines 
Human: 293T ATCC, Middlesex, U.K. RRID:CVCL_0063
Human: Mv4;11 ATCC, Middlesex, U.K. RRID:CVCL_0064
Human: NOMO-1 DSMZ, Germany RRID:CVCL_1609
Human: THP-1 EACC, Salisbury, U.K. RRID:CVCL_0006
 
Analytical platform, Software   
Metabolic assays Metabolon, USA  
FCS express v6 DeNovos Software, California, 
U.S.A
RRID:SCR_016431 
2.2 Methods 77 
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2.2.1 Cell culture 78 
Cell lines were cultured according to recommended conditions at 37⁰C, 5% CO2 for all experiments. 79 
The genetic identity of the cell lines was confirmed by short tandem repeat (STR) at purchase. THP-1 80 
and NOMO-1 cells were lentivirally transduced with shRNA complementary to NOX2 mRNA and 81 
encoding puromycin resistance (THP-1 NOX2-KD or NOMO-1 NOX KD) and control cells (shTHP-82 
1 or shNOMO-1) which had been transfected with shRNA coding for a non-mammalian target 83 
sequence as previously described (Robinson et al., 2020). Additionally, control cells (shTHP-84 
1/NOMO-1) were treated with the NOX inhibitor diphenyleneiodonium (100 nM) for 24 hours prior 85 
to metabolomic analysis. DPI was reconstituted in DMSO and the final concentration was <0.01% 86 
DMSO,This dose has previously been shown to inhibit NOX activity without compromising cell 87 
viability (Robinson et al., 2020). To mimic the effect of NOX2 generated ROS, Mv4;11 cells were 88 
treated with glucose oxidase (GOX; 10 and 20 mU/mL), which catalyzes the production of H2O2 in 89 
cell culture, for 24 hours prior to metabolomic analysis. Control cells were treated with 0.002% v/v 90 
DMSO (Vehicle control).Viability was tested using 7-AAD (1 μg/mL) and analyzed using flow 91 
cytometry; viable cells were used in subsequent superoxide and metabolic assays. 92 
2.2.2 Determination of NOX2 expression 93 
To determine expression levels of NOX2, cells were incubated with NOX2 PE conjugated antibody 94 
(5 ng/μL) or an isotype matched control (MBL), incubated for 45 minutes at 4⁰C and analyzed by 95 
flow cytometry. All flow cytometric data were acquired using an Accuri C6 flow cytometer (Becton 96 
Dickinson, U.K.).  A minimum of 3,000 events collected in the region of interest.  Data analysis was 97 
performed using FCS express v6. 98 
2.2.3 Detection of Superoxide 99 
Cell cultures were adjusted for viable cell number and superoxide measurement carried out using the 100 
chemiluminescent probe Diogenes as previously described (Hole et al., 2010). 101 
2.2.4 Metabolomics 102 
Metabolomic analysis was performed on quadruplicate samples of the AML cell lines THP-1, 103 
NOMO-1 and Mv4;11 by MetabolonTM (http://www.metabolon.com). Cell line samples were 104 
analyzed using ultra-high-performance liquid chromatography mass spectrometry (UPLC-MS), 105 
utilizing Waters ACQUITY UPLC and Thermoscientific Q-Exactive high resolution mass 106 
spectrometer interfaced with a heated electrospray ionization source and Orbitrap mass analyzer. 107 
Raw data was extracted, peaks identified, and quality control processed using proprietary 108 
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MetabolonTM hardware, software, and biochemical library database. Following normalization to 109 
Bradford protein concentration, log transformation and imputation of missing values with the 110 
minimum observed value for each compound, Welch unequal variance two-sample t test was 111 
performed to identify significant differences between the experimental groups. To account for 112 
potentially high false discovery rate (because of multiple comparisons), a q-value was also 113 
calculated, where a lower q-value is an indication of higher confidence in the result. 114 
3 Results 115 
3.1 ROS induce global changes in metabolism in AML cell lines 116 
Our previous study show that NOX2 derived ROS in AML patient blasts increases glucose uptake 117 
(Robinson et al., 2020). These changes in carbohydrate metabolism could also be induced by addition 118 
of GOX (providing a source of exogenous H2O2) in an AML cell line (Mv4;11) that does not 119 
generate NOX2 derived ROS. To establish further evidence that ROS affects metabolism in AML, 120 
we have now analyzed the whole metabolome of AML cell lines producing different levels of NOX-2 121 
derived ROS. Since Mv4;11 cells have very low levels of ROS, we treated these cells with GOX. 122 
Conversely, we have also analyzed the metabolome of lines generating NOX2 derived ROS (THP-1 123 
and NOMO-1) and have examined the impact of knockdown or inhibition of NOX2 in this context 124 
using shRNA vectors and DPI, respectively. To compare NOX2-KD to an appropriate control, we 125 
created control lines infected with non-mammalian target (labelled ‘sh’). The levels of DMSO in 126 
treated samples were less than 0.01%. Given the very low levels of DMSO, we did not treat control 127 
samples with this proportion of DMSO as the effects would be negligible. The knockdown of NOX2 128 
expression / superoxide production (>90% reduction) in THP-1 NOX2 KD as well as the impact of 129 
DPI on THP-1 cells has been previously described (Robinson et al., 2020). Supplemental Figure S1 130 
shows knockdown of NOX2 and reduced superoxide production in NOMO-1 cells. Analysis of the 131 
impact of NOX2 knockdown or inhibition on the global biochemical metabolic profile whose levels 132 
were significantly altered in THP-1 and NOMO-1 cells are shown in Figure 1. Treatment of Mv4;11 133 
cells with H2O2 (mediated by incubation with GOX) resulted in a several significant changes of 134 
biochemical metabolites when cultured with 10 and 20 mU/mL, respectively. Analysis of the overall 135 
biochemical variations between each sample was performed using principal component analysis 136 
(PCA) (Figure 1B). This analysis revealed significant separations -based on the individuality of cell 137 
lines and treatment conditions (i.e., the samples from each AML cell line clustered relatively close to 138 
each other). Due to the limited use of three cell lines, it was not possible to correlate changes with 139 
cell line abnormalities (e.g. mutational or genotypic analysis). However, NOX2 KD and those cells 140 
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treated with DPI showed significant differences of biochemical metabolite levels compared to 141 
shTHP-1/NOMO-1 controls. The largest effects were observed with DPI inhibition. The global 142 
differences between Mv4;11 cells treated/untreated with GOX were much more modest (Figure 1B). 143 
This data is supported by hierarchical clustering where samples also clustered according to genotype 144 
and treatment status (Supplemental Figure S2).  145 
Furthermore, Random Forest (RF) analyses of cellular metabolic profiles (Supplemental Figure S3A 146 
and B) showed 100% prediction accuracy when differentiating shTHP-1 or shNOMO-1 control cells 147 
both from those treated with DPI and cells with NOX2-KD cells; as compared to 33.3% by random 148 
chance alone. Prediction accuracy in differentiating Mv4;11 untreated cells from those treated with 149 
GOX was 91.7% (Supplemental Figure S3C). The high predictive accuracies of the analyses are 150 
consistent with the large number of statistically significant differences between the groups (Figure 151 
1A).  Taken together, these data indicate that whilst cell line origin was the largest determining factor 152 
in changes in global biochemical metabolite variation, culture in a ROS environment affects the 153 
metabolome or global biochemical metabolite composition. 154 
3.2 ROS alters metabolism linked to fatty acid oxidation in AML cell lines 155 
Across all conditions tested above, RF analysis showed consistent changes were observed in lipid 156 
metabolism (Supplemental Figure S3). To determine the NOX2 mediated ROS effects on lipid 157 
metabolism we have compared the common and unique metabolic changes in THP-1 and NOMO-1 158 
cells where NOX2 levels were knocked down (or inhibited) and Mv4;11 cells treated with GOX. 159 
These cell lines showed significant changes in sphingolipid metabolism and FAO (Table 1). Knock-160 
down of NOX2 in THP-1 and NOMO-1 cells significantly decreased levels of sphingomyelins 161 
(phospholipids composed of ceramide and phosphocholine) as well as sphingosine and, in THP-1, 162 
sphinganine metabolites which are involved in their synthesis and degradation (Hait and Maiti, 163 
2017). Levels of sphingosine and sphinganine were also significantly decreased in these cells treated 164 
with DPI (Table 1). Conversely, Mv4;11 cells, significant increases in sphingomyelin levels were 165 
observed upon treatment with GOX (Table 1). Together these data suggest that ROS levels are in 166 
important in regulating sphingolipid synthesis and/or degradation.  167 
It has previously been reported that NOX2 inhibition leads to increased FAO (Adane et al., 2019) and 168 
that FAO can be an important method of ATP production in solid tumors experiencing metabolic 169 
stress (Zaugg et al., 2011;Carracedo et al., 2012). Consistent with this, our data showed that knock-170 
down of NOX2 in THP-1 and NOMO-1 or treatment of cells with DPI led to significant decreases in 171 
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long chain acylcarnitines, metabolites which are consumed during FAO though reciprocal changes 172 
were not seen in Mv4;11 cells treated with GOX (Table 2). NOX2 KD in THP-1 cells displayed 173 
significant decreases in several 3-hydroxy fatty acids (intermediates formed during β-oxidation) and 174 
in free carnitine and its metabolic precursor (deoxycarnitine). Many of the latter metabolites were 175 
lower in the NOMO-1 NOX2 KD cells but fell below the cut-off for statistical significance (Table 2). 176 
Taken together, these data suggest that ROS affects the transport and oxidation of fatty acids. 177 
3.3 ROS alters purine and amino acid homeostasis in NOX2 KD and DPI treated AML cell 178 
lines 179 
It is well established that ROS contributes to enhanced proliferation of leukemia cells including the 180 
cell lines assayed in this study (Hole et al., 2010;Hole et al., 2013;Robinson et al., 2020). Analysis of 181 
our data showed that reduction of ROS levels in THP-1 cells either through NOX2 KD or DPI 182 
treatment, resulted in several alterations in nucleotide metabolism. As shown in Figure 2, notable 183 
changes in purine catabolic/salvage pathway were observed. THP-1 NOX2 KD cells exhibited 184 
significant increases in xanthine, xanthine 5’-monophosphate (XMP) and xanthosine, whilst NOMO-185 
1 cells with reduced levels of NOX2/ROS also showed significant increases in XMP. In parallel with 186 
these changes, THP-1 NOX2 KD cells also exhibited decreases in allantoin and allantoic acid, 187 
metabolites that can be derived from urate (the end-product of purine catabolism), suggesting that 188 
increased Xanthine metabolites are being diverted to adenosine/guanosine synthesis. In addition, 189 
treatment of Mv4;11 with GOX showed a significant increase in xanthine (supplemental 190 
metabolomics file). Whilst XMP and xanthosine levels were increased and a reduction in allantoin 191 
and allantoic acid was observed, these levels were not statistically significant (supplemental 192 
metabolomics file). Taken together, these changes are consistent with alterations in purine utilization 193 
and degradation rates.  194 
AML blasts producing significant levels of ROS show increased levels of metabolites associated with 195 
nucleotide metabolism (Robinson et al., 2020). Significant reductions in the levels of numerous 196 
amino acids were observed in THP-1 cells in which NOX2 was knocked-down or where ROS 197 
production was inhibited by DPI (Table 3). In the shNOMO-1 cell line, similar patterns of amino acid 198 
metabolite levels were observed when the cells were treated with DPI. However, NOX2 KD did not 199 
elicit a change when compared to controls. Decreases were also observed in select dipeptides (short 200 
polymers of amino acids typically derived via protein degradation) (Supplemental metabolomics data 201 
file). Treatment of Mv4;11 cells with H2O2 showed significant increases, at the lower (though not 202 
higher) GOX dosage (Table 3). Together, these data are consistent with the notion where increased 203 
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amino acid production are recycled into metabolic and biosynthetic pathways necessary for increased 204 
proliferation (Rabinowitz and White, 2010). 205 
3.4 ROS alters the glycolytic metabolites pyruvate and lactate in AML cell lines 206 
We previously found that AML blasts with high levels of ROS showed significantly higher levels of 207 
glucose, glucose-6-phosphate, and fructose-6-phosphate (F-6-P), than AML blasts exhibiting low 208 
levels of ROS (Robinson et al., 2020). When THP-1 and NOMO-1 cells with NOX2 KD were 209 
compared to control cells, they exhibited several alterations in metabolites linked to glucose 210 
utilization. While no significant changes in the above metabolites were observed upon modulation of 211 
ROS levels other changes observed were consistent with a role for ROS in promoting glycolysis.  212 
The levels of pyruvate and lactate were significantly lower (1.3 and 1.9-fold respectively) in THP-1 213 
cells with NOX2 KD. In NOMO-1 cells NOX2 KD induced a significant, 2.3-fold decrease in the 214 
glycolytic intermediate fructose-1,6-bisphosphate (F-1,6-BP) indicating decreased flux through the 215 
glycolytic pathway arising from inhibition of ROS production (Figure 3A). Consistent with this data, 216 
shTHP-1 cells treated with DPI also showed a significant decrease 2.2 fold decrease in lactate levels. 217 
Surprisingly, some changes were not supportive of the role of ROS promoting glycolysis. Significant 218 
4.4 fold increases in pyruvate, 8.1 fold increase in 3-phosphoglycerate (3-PG) were observed in THP-219 
1 cells treated with DPI (Figure 3B). A significant increase in 3-PG (3.6-fold) was also observed in 220 
shNOMO-1 cells treated with DPI, whilst significant decreases were observed in F-6-P (3.8-fold), F-221 
1,6-BP (4-fold), dihydroxyacetone phosphate (DHAP; 2-fold) and lactate (2.9-fold) (Figure 3B).  222 
Taken together, these data are consistent with ROS modulated changes in biochemical levels within 223 
the glycolytic pathway.   224 
4 Discussion 225 
Previous work in our group, linked mutational RAS activation with increased NOX2 derived ROS 226 
production and cellular proliferation in normal human hematopoietic cells (Hole et al., 2010). This 227 
was supported by further studies on AML patient blasts and AML cell lines which demonstrated an 228 
association of proliferation with NOX2 derived ROS (Hole et al., 2013). Indeed, a causal link 229 
between ROS and relapse has also been established (Zhou et al., 2010). Further, FLT3-ITD (and 230 
subsequent signaling), another common mutation in AML has also been shown to increase levels of 231 
ROS which was associated with increased DNA double strand breaks (Sallmyr et al., 2008). Elevated 232 
ROS levels have also been observed in other hematological malignancies including acute 233 
lymphoblastic leukemia and chronic myeloid leukemia patient samples (Devi et al., 2000). Beside 234 
  Metabolic rewiring in AML 
 
10This is a provisional file, not the final typeset article 
roles in DNA damage and cell death, there is increasing evidence regarding ROS as a signaling 235 
molecule. Redox signaling can affect transcription factor activity involved in metabolic regulation, 236 
such as HIF1, STAT3 and NF-κB (Zhao et al., 2014). More recently, we identified that ROS 237 
specifically led to changes in mRNA expression levels of several metabolic enzymes including 238 
glycolytic genes (Robinson et al., 2020). We now show here using global metabolomic profiling, the 239 
impact knocking down or inhibiting NOX2 and conversely the effect of exogenous H2O2 on global 240 
cellular metabolism. To address this, we made used of two AML cell lines (THP-1 and NOMO-1) 241 
that constitutively produce extracellular superoxide (ROS) and a cell line with negligible ROS 242 
production (Mv4;11). These models permitted the reciprocal approach to reduce ROS levels (by 243 
knocking down NOX2) or to add exogenous ROS (H2O2) by incubating cells with GOX.  244 
When NOX2 was knocked down in THP-1 and NOMO-1 cell lines, both cell types exhibited 245 
alterations in metabolites linked to FAO and complex lipid homeostasis. Treatment of both these cell 246 
lines with DPI also resulted in changes consistent with the effect of NOX2 derived ROS on 247 
metabolites linked to glucose utilization and amino acid homeostasis. These ROS induced changes in 248 
concentrations of glycolytic metabolites are commensurate with the idea that ROS induces increase 249 
in glucose uptake in these cell lines which leads to metabolic changes and redox adaptation that 250 
supports the enhanced proliferation of leukemia cells (Robinson et al., 2020). However, glycolysis is 251 
only one component of cellular metabolism, with many other metabolic pathways feeding into and 252 
branching off from glycolytic intermediates, such as FAO. Support for the changes observed in lipid 253 
metabolism here, can also be found in recent metabolomic studies in pancreatic ductal 254 
adenocarcinomas, which have identified sphingolipids as relevant biomarkers in this disease 255 
(Daemen et al., 2015).  256 
THP-1 NOX2-KD cells and THP-1 cells treated with DPI exhibited several unique changes, namely, 257 
alterations in metabolites linked to purine metabolism and amino acid homeostasis. Analogous 258 
changes were not observed in NOMO-1 cells with NOX2 KD. NOMO-1 cells generate significantly 259 
larger amounts of ROS than THP-1 cells (Supplemental Figure S1) and given that the knock-down of 260 
NOX2 in these cells was only partial, it may be that cellular ROS remained at high enough levels in 261 
these cells to prevent equivalent changes occurring. Interestingly, NOMO-1 cells treated with DPI 262 
and exhibiting lower levels of ROS than those with NOX2 knocked down, showed similar changes in 263 
purine metabolites and amino acid levels to those in the THP-1 cells. Additionally, it is worth noting 264 
that changes in purine synthesis and catabolism could in themselves influence ROS production, as 265 
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H2O2 is produced as a co-product by the enzyme xanthine oxidase (XO; the enzyme responsible for 266 
metabolizing xanthine to urate). In addition to these changes, THP-1 and NOMO-1 cells also 267 
exhibited decreases in the purine synthetic intermediate AICA ribonucleotide and increases in the 268 
pyrimidine synthetic intermediate orotate (Supplemental Metabolomics data file).  269 
The data generated from the addition of GOX to Mv4;11 cell line was more equivocal particularly at 270 
the higher dose of GOX. Addition of GOX at the lower (10mU/mL) dose demonstrated changes to 271 
both sphingolipid metabolism and amino acid homeostasis consistent with the data generated in the 272 
THP-1 and NOMO-1 cell lines. Culture with GOX did not dose dependently increase the various 273 
sphingolipids and other sphingomyelins. It suggests higher GOX levels maybe toxic but we did not 274 
observe changes in cell viability. Alternatively, it is interesting to speculate that higher levels of 275 
GOX are activating a negative feedback loop.  Little effect was observed on purine synthesis and the 276 
impact on FAO. FAO is known to be negatively correlated with ROS production (Schafer et al., 277 
2009) and is an important source of NADPH. NADPH is also generated via the pentose phosphate 278 
pathway (PPP) and serine synthesis pathway and discrepancies here may simply be reflective of 279 
differing relative cellular utilization of alternative antioxidant generating pathways. Overall, the more 280 
modest changes in this cell line may be reflective of the smaller variation between the untreated and 281 
treated samples, as revealed by the PCA analysis (Figure 1B), when compared with those observed in 282 
the other two cell lines.  283 
The biochemical changes arising from the DPI treatment noted several common alterations, however, 284 
there were some degree of differences within the THP-1 and NOMO-1 cells. Specifically, both cell 285 
lines exhibited alterations in metabolites linked to glucose utilization, TCA cycle activity, lipid 286 
availability, nucleotide turnover, nicotinamide metabolism, and amino acid homeostasis. It is 287 
recognized that at micro-molar concentrations, DPI inhibits not only NOX but also mitochondrial 288 
respiration through the inhibition of NAPDH cytochrome P450 oxidoreductase, as well as, nitric 289 
oxide synthase, and xanthine oxidase (reviewed in (Aldieri et al., 2008)). Additionally, it has been 290 
reported (Riganti et al., 2004) that DPI inhibits not only the TCA but also the PPP, the first step of 291 
which regenerates NADPH, an important reducing agent for ROS. Inhibition of the citric acid cycle 292 
could potentially explain increases in extracellular lactate as an accumulation of pyruvate (the final 293 
product of glycolysis) would also generate proportional increases in the concentration of intracellular 294 
lactate. However, the levels of DPI used (in nanomolar range) over the time course of incubation (24 295 
h) does not significantly affect cell viability or mitochondrial superoxide production (Hole et al., 296 
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2010). Further, it has also been suggested that at nano-molar concentrations, inhibition of NOX but 297 
not mitochondrial respiration is observed (Bulua et al., 2011).  298 
Otto Warburg initially ascribed his observation that cancer cells exhibited increased aerobic 299 
glycolysis to defective mitochondrial function in these cells (Warburg, 1956), although a number of 300 
subsequent studies have shown functional mitochondria is important in cancer cell metabolism 301 
(reviewed in (Wallace, 2012)). The citric acid cycle commences from the reaction of acetyl CoA with 302 
oxaloacetate to form citrate. Acetyl CoA is generated following the decarboxylation of pyruvate 303 
catalyzed by the enzyme pyruvate dehydrogenase, whilst oxaloacetate is regenerated from the citric 304 
acid cycle. Importantly the metabolic step which converts succinate to fumarate involves the 305 
reduction of flavin adenine dinucleotide which generates the proton gradient necessary for oxidative 306 
phosphorylation. Furthermore, it has been shown that whilst hematopoietic stem cells require 307 
fumarate hydratase (the enzyme that catalyzes this step) for self-renewal and maintenance, leukemia 308 
stem cells do not (Guitart et al., 2017). Therefore, ROS induced changes in fumarate levels may be 309 
indicative of changes in the cellular rates of oxidative phosphorylation. Analysis of the mass 310 
spectrometry data by MetabolonTM showed no significant changes in fumarate levels in either THP-1 311 
or NOMO-1 cells with NOX2 KD but significant decreases were observed in DPI treated cells 312 
(Supplemental Figure S4). It should be noted that decreases in fumarate metabolites could have 313 
arisen from DPI’s inhibitory effect on flavoproteins independent of NOX. Taken together, these data 314 
suggest that genetic knock down of NOX2 in THP-1 and NOMO-1 cells does not affect the rate of 315 
oxidative phosphorylation.  316 
In summary, exposure of cells to NOX2 derived ROS is consistent with cellular alterations in protein 317 
degradation rates, amino acid utilization, lipid metabolism and energy production. Changes of this 318 
nature may correlate with alterations in growth and proliferation rates.  319 
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12 Figure Legends 414 
Figure 1.  Production of ROS is associated with global changes in metabolism in AML cell lines.  415 
Data from global biochemical profiling of shTHP-1, shNOMO-1 and Mv4;11 AML cell lines. THP-416 
1/NOMO-1 cells with NOX2 knocked down using shRNA (NOX2-KD), compared to control cells 417 
infected with non-mammalian targeting control shRNA (control) or 100nM DPI, a NOX inhibitor. 418 
Mv4;11 cells were treated with 10 mU/mL or 20 mU/mL GOX (compared to untreated control). (A) 419 
Summary of the numbers of biochemicals that achieved statistical significance (*p≤0.05) analyzed by 420 
Welch’s two sample t-test. (B) Principal components analysis (PCA) of global biochemical profiling 421 
of AML cell lines cells. Sh controlcells were treated with 100nM DPI for 24h or NOX2 was KD 422 
using shRNA (n=4). Mv4;11 cells were treated with 10 or 20 mU/mL of GOX for 24 h (n=4).  423 
Figure 2.  Alterations in purine metabolism in NOX2 KD and DPI-Treated AML cell lines.  424 
Data from global biochemical profiling of shTHP-1 and shNOMO-1 cells with NOX2 KD or treated 425 
with DPI (100 nM) for 24 h followed by analysis by MetabolonTM. Levels of biochemicals 426 
normalized to total protein in purine metabolism. Statistical significance analyzed by Welch’s two 427 
sample t-Test (n=4 per group) and significance denoted by *, P<0.05. Ctrl, untreated control cells; 428 
XMP, xanthosine 5’-monophosphate; GMP, guanosin-monophosphate; XO, xanthine oxidase. THP-1 429 
cells are color coded (blue) and NOMO-1 cells color coded Red. Y axis is scaled intensity.  430 
Figure 3. Changes in glycolytic intermediates in AML derived cell lines with NOX2 KD or 431 
treated with DPI. Significant changes in glycolytic metabolites in (A) shTHP-1 and shNOMO-1 432 
cells with NOX2 KD. (B) shTHP-1 and shNOMO-1 cells treated with DPI (100nM) for 24h. Data 433 
shows relative values following normalization to protein concentration, log transformation and 434 
imputation of missing values with the minimum observed value for each compound (n=4). Box plots 435 
represent median quartile ranges, x represents mean value. * denotes p<0.05 = as analyzed by 436 
Welch’s two sample t-test. THP-1 cells are color coded (blue) and NOMO-1 cells color coded green.  437 
Table 1. Exposure of AML cell lines to ROS is associated with global changes in sphingolipid 438 
metabolism. Table shows mean fold changes in sphingolipids in THP-1 and NOMO-1 cells with 439 
NOX2 KD when compared to controls (transduced with control shRNA vector). Changes in 440 
sphingolipids were also compared in shTHP-1 and shNOMO-1 cells treated with DPI (100 nM) for 441 
24 h or Mv4;11 cells treated with increasing GOX units/mL. Data shows relative values following 442 
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normalization to protein concentration, log transformation and imputation of missing values with the 443 
minimum observed value for each compound (n=4). Color boxes indicate ratios and p-values for each 444 
comparison:.boxes shaded dark green indicate significant decreases and boxes shaded dark red 445 
indicate significant increases; statistical significance was performed using Welch’s two sample t-test 446 
(P<0.05). Boxes shaded light green or red indicate decreases or increases, respectively and 447 
approaching significance (p<0.1).  448 
Table 2.  Exposure of AML cell lines to ROS is associated with global changes FAO 449 
metabolism. Table shows mean fold changes in fatty acid oxidation in THP-1 and NOMO-1 cells 450 
with NOX2 KD when compared to controls (transduced with control shRNA vector). Changes in 451 
sphingolipids were also compared in shTHP-1 and shNOMO-1 cells treated with DPI (100 nM) for 452 
24 h or Mv4;11 cells treated with increasing GOX units/mL. Data shows relative values following 453 
normalization to protein concentration, log transformation and imputation of missing values with the 454 
minimum observed value for each compound (n=4). Color boxes indicate ratios and p-values for each 455 
comparison: boxes shaded dark green indicate significant decreases and boxes shaded dark red 456 
indicate significant increases; statistical significance was performed using Welch’s two sample t-test 457 
(P<0.05). Boxes shaded light green or red indicate decreases or increases, respectively and 458 
approaching significance (p<0.1). 459 
Table 3 Exposure of AML cell lines to ROS is associated with global changes in amino acid 460 
metabolism. Table shows mean fold changes in amino acids in THP-1 and NOMO-1 cells with 461 
NOX2 KD when compared to controls (transduced with control shRNA vector). Changes in 462 
sphingolipids were also compared in shTHP-1 and shNOMO-1 cells treated with DPI (100 nM) for 463 
24 h or Mv4;11 cells treated with increasing GOX units/mL. Color boxes indicate ratios and p-values 464 
for each comparison: data shows relative values following normalization to protein concentration, log 465 
transformation and imputation of missing values with the minimum observed value for each 466 
compound (n=4). Boxes shaded dark green indicate significant decreases and boxes shaded dark red 467 
indicate significant increases; statistical significance was performed using Welch’s two sample t-test 468 
(P<0.05). Boxes shaded light green or red indicate decreases or increases, respectively and 469 





















(d18:0/16:0) 0.68 0.49 1.30 0.81 2.27 2.88 
sphinganine 0.82 0.47 1.10 0.30 1.06 0.99 
phytosphingosine 0.65 0.80 0.81 0.63 1.12 1.13 
palmitoyl sphingomyelin 
(d18:1/16:0) 0.80 1.22 0.85 0.98 1.09 0.89 
stearoyl sphingomyelin 
(d18:1/18:0) 0.82 1.10 0.65 0.96 1.31 1.04 
sphingomyelin (d18:1/18:1, 
d18:2/18:0) 0.89 1.16 0.61 0.96 1.39 1.14 
sphingosine 0.62 0.37 0.70 0.30 1.13 1.00 
N-palmitoyl-sphingosine 
(d18:1/16:0) 0.76 1.68 0.88 1.27 1.08 0.88 
sphingomyelin (d18:1/14:0, 
d16:1/16:0)* 0.80 1.32 0.88 1.22 1.15 0.96 
sphingomyelin (d18:2/14:0, 
d18:1/14:1)* 0.77 1.24 0.85 1.16 1.45 1.37 
sphingomyelin (d18:1/24:1, 
d18:2/24:0)* 0.81 1.17 0.85 0.85 1.32 1.06 
sphingomyelin (d18:2/16:0, 
d18:1/16:1)* 0.78 1.07 0.88 0.91 1.35 1.19 
sphingomyelin (d18:1/20:1, 
d18:2/20:0)* 0.81 0.92 0.76 1.21 1.76 1.43 
behenoyl sphingomyelin 
(d18:1/22:0)* 0.83 1.11 0.83 1.08 1.44 1.14 
sphingomyelin (d18:1/22:1, 
d18:2/22:0, d16:1/24:1)* 0.79 1.09 0.89 1.26 1.72 1.43 
sphingomyelin (d18:1/20:0, 
d16:1/22:0)* 0.82 1.00 0.86 1.16 1.46 1.20 
palmitoyl dihydrosphingomyelin 
(d18:0/16:0)* 1.09 0.93 1.18 0.64 2.23 2.10 
sphingomyelin (d18:1/15:0, 
d16:1/17:0)* 0.77 1.14 0.87 1.07 1.19 1.04 
sphingomyelin (d18:1/21:0, 
d17:1/22:0, d16:1/23:0)* 0.79 0.96 0.79 1.44 1.70 1.52 
sphingomyelin (d18:2/23:0, 
d18:1/23:1, d17:1/24:1)* 0.77 1.09 0.74 1.09 1.59 1.35 
sphingomyelin (d18:2/24:1, 
d18:1/24:2)* 0.74 1.14 0.78 0.97 1.60 1.33 
tricosanoyl sphingomyelin 
(d18:1/23:0)* 0.80 1.16 0.76 1.11 1.70 1.47 
sphingomyelin (d18:1/17:0, 
d17:1/18:0, d19:1/16:0) 0.74 1.03 0.71 1.09 1.39 1.23 
glycosyl-N-stearoyl-sphingosine 0.70 0.97 0.70 0.97 0.94 0.70 
glycosyl-N-palmitoyl-sphingosine 0.62 0.91 0.90 0.99 1.10 0.91 
lactosyl-N-palmitoyl-sphingosine 0.86 0.97 0.93 0.90 1.00 0.83 




















hexanoylcarnitine 0.16 0.05 0.29 0.04 0.50 0.29 
octanoylcarnitine 0.27 0.27 0.19 0.12 2.08 0.78 
laurylcarnitine 0.56 0.19 0.48 0.21 0.83 0.69 
myristoylcarnitine 0.48 0.23 0.53 0.21 0.76 0.65 
palmitoylcarnitine 0.45 0.18 0.58 0.15 0.66 0.56 
stearoylcarnitine 0.40 0.06 0.74 0.09 0.63 0.57 
linoleoylcarnitine 0.12 0.38 1.26 0.74 1.09 0.63 
oleoylcarnitine 0.34 0.40 0.56 0.24 1.03 0.68 
myristoleoylcarnitine 0.45 0.39 0.46 0.34 1.08 0.79 
suberoyl carnitine 0.87 0.68 1.20 0.88 0.84 0.92 
deoxycarnitine 0.57 1.09 0.85 0.68 0.86 0.69 
carnitine 0.62 0.96 0.90 0.80 0.94 0.74 
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Glycine 0.75 1.31 1.02 0.84 1.11 0.85 
Serine 0.78 0.37 1.19 0.63 1.09 0.72
Threonine 0.77 0.83 1.10 0.51 1.28 1.00
Alanine 0.75 0.57 1.19 0.43 0.98 0.73
Asparagine 0.67 0.64 1.25 0.48 1.13 0.86
Glutamate 0.75 0.95 0.95 0.90 1.06 0.82
Glutamine 0.16 1.64 1.27 0.42 1.14 0.73
Histidine 0.81 0.74 1.16 0.72 1.28 0.97
Phenylalanine 0.79 0.51 1.06 0.65 1.18 0.91
Tryptophan 0.80 0.63 1.12 0.70 1.23 1.03
Leucine 0.77 0.64 1.07 0.71 1.16 0.86
Methionine 0.83 0.63 1.14 0.86 1.20 0.82
Cysteine 0.52 1.08 0.83 0.79 1.19 0.97
Proline 0.74 0.89 0.88 0.71 1.23 1.03
Aspartate 1.38 0.54 0.77 0.41 0.84 0.64
Arginine 0.93 1.32 1.06 0.86 1.09 0.78
Isoleucine 0.82 0.89 1.13 0.84 1.28 1.03
Valine 0.85 0.73 1.06 0.73 1.28 0.95
Lysine 0.86 0.84 0.91 0.63 1.15 0.89
Tyrosine 0.74 0.47 1.11 0.68 1.18 0.92
  

























Cell line Comparison Total Biochemicals 





shControl  198 49/149 
DPI/ 
















Control 204 96/108 



























































































































Pyruvate Lactate F-1,6-BP A 
B 
Lactate Pyruvate 3-PG 
F-6-P F-1,6-P DHAP * * *
*
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